RSWM
ALNY icon

Robertson Stephens Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Robertson Stephens Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$837K Sell
2,782
-54
-2% -$16.3K 0.02% 349
2026
Q1 		$938K Buy
2,836
+36
+1% +$12.3K 0.03% 312
2025
Q4 		$1.11M Buy
+2,800
New +$1.24M 0.03% 279

Other funds holding ALNY

Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robertson Stephens Wealth Management's ALNY Position: Q2 2026 in Review

Robertson Stephens Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.9% in Q2 2026, selling an estimated $16.3K and leaving 2,782 shares worth $837K. The position accounts for 0.02% of the portfolio, ranked #349.

Robertson Stephens Wealth Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.11M in Q4 2025. 306 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Robertson Stephens Wealth Management held 2,782 shares of Alnylam Pharmaceuticals worth $837K as of Q2 2026.
  • Robertson Stephens Wealth Management sold 54 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.3K.
  • Alnylam Pharmaceuticals made up 0.02% of Robertson Stephens Wealth Management's portfolio in Q2 2026, its #349 holding.
  • Robertson Stephens Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Robertson Stephens Wealth Management's Alnylam Pharmaceuticals position peaked at $1.11M in Q4 2025.
  • 306 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.